Vasculitis & polymyalgia rheumatica
IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients
Authors' conclusion
The baseline presentation of IgAV following COVID-19 vaccination was mild to moderate, and outcomes were favorable.
Study context
- Population
- Adults with new-onset IgA vasculitis (IgAV) diagnosed after COVID-19 vaccination, France5 (41.7%) women
- Participants
- 12 adults
- Exposure
- mRNA vaccine vs Viral vector vaccine
- mRNA vaccinen = 10
- Viral vector vaccinen = 2
- Outcome
- Presentation of IgAV after COVID-19 vaccination
Methodological detailsnational, multicenter
- National
- Multicenter
Main finding
As reported in the abstract
- Age, median (IQR 30.75-60.5) years
- 52.5
- Time from vaccination to symptom onset, median (IQR 4.25-21.25) days
- 11.5
- Vasculitis after first vaccine dose, n
- 8
- Skin involvement
- All patients
- Skin necrosis, n
- 4
- Joint involvement, n
- 7
- Arthritis, n
- 2
- Nonsevere gastrointestinal involvement, n
- 4
- Nonsevere renal involvement, n
- 2
- CRP, median (IQR 10-66.75) mg/L
- 26
- Creatininemia, median (IQR 65-81) μmol/L
- 72
- eGFR <60 mL/min at management, n
- 1
- All received treatment; GC, n (%)
- 9 (75%)
Observational data: associations, not effects.
Further findings
Vaccine dose after developing IgAV
- Patients revaccinated, n
- 5
- Minor cutaneous relapse among revaccinated, n
- 1
Original publication
IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →